TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Teva to Present at the Jefferies 2017 Global Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Jefferies 2017 Global Healthcare Conference in New York, NY.

When:

  Wednesday, June 7, 2017 at 2:30 PM ET
 
 

Who:

Dr. Yitzhak Peterburg, Interim President & CEO,
Dr. Michael Hayden, President of Global R&D & Chief Scientific Officer,
Dipankar Bhattacharjee, President & CEO Global Generic Medicines,
Teva Pharmaceutical Industries Ltd.
 
 

Where:

http://ir.tevapharm.com

 
 

How:

Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s Website at http://ir.tevapharm.com.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.

EN
06/06/2017

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The F...

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration1AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention ...

Si Yong Ng
  • Si Yong Ng

Teva - Earnings Flash - Q2 FY 2025 Results - Lucror Analytics

Teva has reported good Q2/25 numbers, with adjusted EBITDA rising y-o-y. While reported sales were broadly flat, they would have increased if adjusting for the disposal of the Japan business venture (BV). Cash generation improved. Reported net leverage was broadly flat q-o-q, while liquidity remained adequate. We anticipate decent H2/25 results, with continued top-line-supported growth in Austedo, Ajovy and Uzedy to offset headwinds from the Japan BV disposal. Profitability should benefit fr...

Josseline Jenssen ... (+2)
  • Josseline Jenssen
  • Si Yong Ng

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: GOL, Teva

Felix Fischer ... (+7)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
  • Trung Nguyen

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Trivium, Applus, Altice France (SFR), Casino Guichard-Perrachon, International Personal Finance, TeamSystem, Aston Martin, Virgin Media O2, Liberty Global, TalkTalk, Recordati, Tata Motors, Nexans, Italmatch Chemicals, Itelyum Group, Teva

 PRESS RELEASE

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth i...

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy.Q2 2025 shows 10th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local currencyterms (“LC“)excluding Japan BV revenues; United States segment +2%; Europe segment +3% in LC; International Markets segment -4% inLCand excluding Japan BV revenues. Innovative portfolio continu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch